Unknown

Dataset Information

0

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.

ABSTRACT: In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

SUBMITTER: Branche AR 

PROVIDER: S-EPMC10443997 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.

Branche Angela R AR   Rouphael Nadine G NG   Losada Cecilia C   Baden Lindsey R LR   Anderson Evan J EJ   Luetkemeyer Anne F AF   Diemert David J DJ   Winokur Patricia L PL   Presti Rachel M RM   Kottkamp Angelica C AC   Falsey Ann R AR   Frey Sharon E SE   Rupp Richard R   Bäcker Martín M   Novak Richard M RM   Walter Emmanuel B EB   Jackson Lisa A LA   Little Susan J SJ   Immergluck Lilly C LC   Mahgoub Siham M SM   Whitaker Jennifer A JA   Babu Tara M TM   Goepfert Paul A PA   Fusco Dahlene N DN   Atmar Robert L RL   Posavad Christine M CM   Netzl Antonia A   Smith Derek J DJ   Telu Kalyani K   Mu Jinjian J   Makowski Mat M   Makhene Mamodikoe K MK   Crandon Sonja S   Montefiori David C DC   Roberts Paul C PC   Beigel John H JH  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20230801 4

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines. ...[more]

Similar Datasets

Unknown Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.
| S-EPMC10081431 | biostudies-literature
Unknown Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection.
| S-EPMC10826328 | biostudies-literature
Unknown Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
| S-EPMC8807272 | biostudies-literature
Unknown Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
| S-EPMC9847505 | biostudies-literature
Unknown Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
| S-EPMC9353262 | biostudies-literature
Unknown Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters.
| S-EPMC9628195 | biostudies-literature
Genomics Severe acute respiratory syndrome coronavirus 2 strain:Omicron BA.1
| PRJNA888402 | ENA
Unknown High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
| S-EPMC9278180 | biostudies-literature
Unknown Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
| S-EPMC8242375 | biostudies-literature
Unknown Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients.
| S-EPMC9995387 | biostudies-literature